New eczema drug candidate tested in healthy people for first time
NCT ID NCT06920693
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 22 times
Summary
This early-stage study tests a new medicine called GB-7624 in 40 healthy adults to see if it is safe and how the body processes it. The study has two parts: one group gets a single dose, and another gets two doses over two weeks. This research is a first step toward possibly treating atopic dermatitis (eczema) in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Generate Biomedicines Clinical Site
Herston, Queensland, 4007, Australia
Conditions
Explore the condition pages connected to this study.